Caribou Biosciences (CRBU) Jefferies Global Healthcare Conference 2026 summary

Program overviews and clinical progress

• Advancing two off-the-shelf CAR T cell therapy programs: vispa-cel for non-Hodgkin lymphoma (pivotal-ready) and CB-011 for multiple myeloma (in phase I).

• vispa-cel phase I data show outcomes on par with autologous CAR T therapies; pivotal phase III (ANTLER III) is planned.

• CB-011 demonstrated response rates exceeding bispecific antibodies and approaching autologous CAR T levels; dose expansion data expected later this year.

ANTLER III pivotal study design and strategy

• Randomized controlled trial targeting second-line large B-cell lymphoma patients who are ineligible or unable to access autologous CAR T or stem cell transplant.

• Control arm uses investigator's choice of chemoimmunotherapy regimens, all with similar median PFS (~4.5 months).

• FDA endorsed enrolling both medically ineligible and access-challenged patients; crossover to vispa-cel allowed for control arm progression.

• Study will enroll 250 patients globally, leveraging both academic and community hospitals.

• Primary endpoint is event-driven progression-free survival; expected study duration is about two years from initiation to data.

Market landscape and competitive positioning

• 75% of second-line patients do not receive autologous CAR T due to urgency and access barriers; vispa-cel aims to address both.

• vispa-cel offers immediate availability and potential for community-based delivery, reducing wait times.

• Market research indicates strong physician enthusiasm for vispa-cel as a one-and-done, off-the-shelf therapy.

• Bispecific antibody approvals are not expected to significantly impact vispa-cel’s addressable market.